DTRA

Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever

Retrieved on: 
Wednesday, March 20, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, DTRA, Conditional sentence, Inflammation, Viral, Marburg virus disease, Human, TLR7, Therapy, Lassa mammarenavirus, Lassa fever, Bleeding, Toll-like receptor 7, Vaccine

Primmune Therapeutics , a biotech company harnessing the power of the innate immune system, today announced that it was awarded a $22,480,552 contract by the Defense Threat Reduction Agency (DTRA) to develop PRTX007 as an oral broad spectrum antiviral TLR7 agonist for the treatment of Lassa fever.

Key Points: 
  • Primmune Therapeutics , a biotech company harnessing the power of the innate immune system, today announced that it was awarded a $22,480,552 contract by the Defense Threat Reduction Agency (DTRA) to develop PRTX007 as an oral broad spectrum antiviral TLR7 agonist for the treatment of Lassa fever.
  • The objective of the program is to evaluate the efficacy of PRTX007 in a series of animal models for Lassa fever and establish an effective treatment method of Lassa virus in humans.
  • “Primmune has demonstrated broad spectrum antiviral activity with PRTX007 and with related compounds from our discovery and development program,” said Charlie McDermott, President, Chief Executive Officer and Director of Primmune Therapeutics.
  • “PRTX007’s novel immunologic approach has the potential for combination use with direct acting anti-viral agents – enabling widely applicable utility in the treatment of Lassa fever and other hemorrhagic viruses.”

EverGlade Funding Alert - ARPA-H Announces Mission Office-Specific Funding Opportunities

Retrieved on: 
Tuesday, March 19, 2024
DTRA, Organization, Biomedical Research, BAA, NIH, Consultant, DOD, Public sector, ARPA, ASPR, Mission, Multimedia, DARPA, ISO, DOE, Medical device

HOUSTON, March 19, 2024 /PRNewswire/ -- The Advanced Research Projects Agency for Health (ARPA-H) has announced a new funding opportunity through its Mission Office-specific Innovative Solution Openings (ISO). The funding opportunity aims to accelerate innovation and breakthroughs in health research by providing targeted support to projects aligned with ARPA-H's mission areas.

Key Points: 
  • The funding opportunity aims to accelerate innovation and breakthroughs in health research by providing targeted support to projects aligned with ARPA-H's mission areas.
  • The Mission Office Open ISOs represents a strategic effort by ARPA-H to focus resources on key priority areas, fostering collaboration and innovation within the health research community.
  • Through this opportunity, ARPA-H aims to address critical challenges in healthcare and drive transformative advances in biomedical research.
  • If your company has considered applying for ARPA-H funding, your federal funding journey starts here.

Doug Bruder Joins ARA as Director, National Security Programs

Retrieved on: 
Monday, February 26, 2024
Bruder, Senior, GlobalSecurity.org, Assistant, Defense, Government, Distinguishing, DTRA, ARA, DOE, Development, Management

Albuquerque, NM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Applied Research Associates, Inc. (ARA) is pleased to announce the hiring of Doug Bruder as Director, National Security Programs focusing on ARA’s national security enterprise.

Key Points: 
  • Albuquerque, NM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Applied Research Associates, Inc. (ARA) is pleased to announce the hiring of Doug Bruder as Director, National Security Programs focusing on ARA’s national security enterprise.
  • Bruder brings 40 years of experience in national security and has led numerous technology-driven national security programs across government and industry.
  • Following his Government career, Bruder served as a Vice President and Strategic Account Executive for Leidos, and as the Associate Laboratories Director for Global Security at the Sandia National Laboratories.
  • “We are pleased that Doug is joining ARA and excited to work with him on new ARA growth activities,” said James Kainz, Senior Vice President, Corporate Business Development.

EverGlade Funding Alert - $300 Million Funding Opportunity Announced for CHIPS National Advanced Packaging Manufacturing Program (NAPMP)

Retrieved on: 
Monday, March 4, 2024
CHIPS, DARPA, Outline, Multimedia, DOD, NIH, Government, Public sector, Glass, ASPR, DTRA, DOE, Research, Renewable energy

HOUSTON, March 4, 2024 /PRNewswire/ -- The U.S. government, through CHIPS for America, has announced a groundbreaking funding opportunity aimed at bolstering domestic research and development (R&D) in advanced semiconductor packaging materials and substrates. The initiative, part of the National Advanced Packaging Manufacturing Program (NAPMP), is set to inject approximately $300 million into innovations spanning semiconductor-based materials to glass and organics. This funding opportunity marks a significant step in the U.S.'s commitment to maintaining and advancing its leadership in the global semiconductor industry.

Key Points: 
  • The initiative, part of the National Advanced Packaging Manufacturing Program (NAPMP), is set to inject approximately $300 million into innovations spanning semiconductor-based materials to glass and organics.
  • This funding opportunity marks a significant step in the U.S.'s commitment to maintaining and advancing its leadership in the global semiconductor industry.
  • "This funding opportunity represents a pivotal moment for the U.S. semiconductor industry.
  • If your company has considered applying for CHIPS funding, your federal funding journey starts here.

EverGlade Consulting Funding Alert: ARPA-H Transitions to Mission Office-Specific Innovation Solutions Openings to Allow Funding Under Cooperative Agreements and OTAs

Retrieved on: 
Thursday, February 22, 2024
DARPA, ARPA, Mission, BAA, Multimedia, NIH, Federal Acquisition Regulation, News, Federation, Public sector, Open, ASPR, Optical disc image, DTRA, Research

HOUSTON, Feb. 22, 2024 /PRNewswire/ -- The Advanced Research Projects Agency for Health ("ARPA-H") recently announced a shift in how the agency will fund health-related technology research and development. ARPA-H will transition to Mission Office-Specific Innovation Solutions Openings (ISOs) to allow funding under cooperative agreements and "other transactions". This change provides flexibility outside the traditional grant and contract structure governed by Federal Acquisition Regulation, making it possible for non-traditional government contractors to apply for and receive ARPA-H funding.

Key Points: 
  • ARPA-H will transition to Mission Office-Specific Innovation Solutions Openings (ISOs) to allow funding under cooperative agreements and "other transactions".
  • Effective March 14, 2024, ARPA-H will close the current Open-Office BAA and transition to Mission Office ISOs.
  • Effective March 14, 2024, ARPA-H will close the current Open-Office Broad Agency Announcement (BAA) and transition to Mission Office ISOs.
  • If your company is interested in pursuing ARPA-H funding and navigating the changes implemented with Mission Office ISOs, EverGlade Consulting is the right partner to help.

Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design

Retrieved on: 
Thursday, February 15, 2024
DNA, Saponin, GMD, Toxicity, Enzyme, Ginkgo Bioworks, Medicine, SVP, Partnership, Animal, Vaccine, ADC, Refrigeration, Vaccination, Shingles, Malaria, COVID-19, Respiratory syncytial virus, Chemical substance, Saccharomyces cerevisiae, CBD, DTRA, Protein, MCDC, QS-21, Plague, Ginkgo

Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination.

Key Points: 
  • Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination.
  • Currently, only a handful of adjuvants are available for human use in licensed vaccines.
  • Ginkgo will develop a first-generation Adjuvant Development Candidate (ADC) production method, using a heterologous production strain such as brewers' yeast, Saccharomyces cerevisiae.
  • Development of a first-generation ADC production method could facilitate further development of a sustainable mass-production manufacturing process for these complex adjuvants.

ReAlta Life Sciences Strengthens Board of Directors with Appointment of Two Accomplished Biotechnology Innovators

Retrieved on: 
Wednesday, January 24, 2024
Research, Clinical Trials, Health Technology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Artificial intelligence, NSRI, University, Patient, Principal, Executive Committee, UARC, Government, JHUAPL, Partnership, Containerization, Epigenome, GSK, Diagnosis, DTRA, Drug discovery, Chemical engineering, COVID-19, Applied Physics Laboratory, Biomedical engineering, CBCS, Department of Defence, DARPA, Therapy, Doctor of Philosophy, Traumatic brain injury, Nursing care plan, Machine learning, Pennsylvania State University, STRATCOM, MRIGlobal, SVP, ARA, Medical device

“We are delighted to welcome Dr. Baldoni and Dr. Van Gieson to our Board of Directors and look forward to their expertise as we continue to advance our EPICC platform beyond our current portfolio,” said Buzz Heidt, Chairman of ReAlta’s Board of Directors.

Key Points: 
  • “We are delighted to welcome Dr. Baldoni and Dr. Van Gieson to our Board of Directors and look forward to their expertise as we continue to advance our EPICC platform beyond our current portfolio,” said Buzz Heidt, Chairman of ReAlta’s Board of Directors.
  • Dr. Baldoni’s Platform Technology and Science team supported the development of small molecules, biopharmaceuticals and cell and gene therapy modalities from discovery through commercialization.
  • Dr. Baldoni stepped away from that leadership role in 2017 to start the first AI-driven drug discovery unit at GSK.
  • After retiring from GSK in 2019, he spent a year as the Chief Technology Officer of a stealth AI-enabled drug discovery startup.

EverGlade Consulting Celebrates Continued Growth with New Office Opening in Washington, D.C.

Retrieved on: 
Wednesday, January 10, 2024
ASPR, DOE, Heart, Health, Consultant, DOC, Multimedia, Government, DTRA, Massachusetts Avenue, ARPA, NIH, HHS, NIAID, DARPA, Public sector, DOD, Growth, Renewable energy

CHARLESTON, S.C., Jan. 10, 2024 /PRNewswire/ -- EverGlade Consulting, a leader in consultancy for government contractors across life sciences, technology, health, and defense industries, proudly announces the opening of its newest office in Washington, D.C. Situated at the bustling Industrious location at 650 Massachusetts Avenue NW, this expansion is a testament to EverGlade's sustained growth and commitment to offering expert consulting services.

Key Points: 
  • This move allows EverGlade to be in close proximity to key government agencies, enhancing its ability to provide immediate, informed, and comprehensive consulting services.
  • If your company has considered applying for government funding, EverGlade Consulting is the right partner to help make that application a reality.
  • EverGlade Consulting is a national consulting firm connecting public sector needs with private sector solutions.
  • For additional information about EverGlade Consulting, reach out to:
    View original content to download multimedia: https://www.prnewswire.com/news-releases/everglade-consulting-celebrates...

NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University

Retrieved on: 
Thursday, December 21, 2023
Work, Annual report, Research, CDMO, DTRA, Defense Threat Reduction Agency, Growth, NIH, Scorpius

DURHAM, N.C., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced its Scorpius BioManufacturing subsidiary (“Scorpius”) completed a demonstration run in the Company’s process development lab for a microbial vaccine program developed by a top-tier research university that is NIH and DTRA (Defense Threat Reduction Agency) funded.

Key Points: 
  • Jeff Wolf, CEO of NightHawk, commented, “This first phase of a multi-million-dollar project was particularly noteworthy, as we achieved a successful demonstration run following a prior failed attempt by a competitor CDMO.
  • The complexity of the project led this top-tier university to choose Scorpius, drawn by our more engaged management approach and accelerated development timeline.
  • The successful completion of this demonstration run showcases our team's dedication and expertise, and represents an important step in advancing our relationship with this nationally renowned university.
  • The next phase of this project will include scaling up to cGMP manufacturing to support a phase 1 infectious disease trial.

First Human Clinical Study to Assess U.S. Department of Defense DNA Vaccine Candidate against Venezuelan Equine Encephalitis Delivered with PharmaJet Precision Delivery Systems.

Retrieved on: 
Thursday, November 16, 2023
Medical Devices, Medical Supplies, Homeland Security, Public Policy, Government, Clinical Trials, Biotechnology, White House, Federal Government, Health, Pharmaceutical, Stratis, ID, Institutional review board, MCDC, VEE, DNA, IRB, Alphavirus, Clinical trial, Mortality, Epidemic, DTRA, FDA, Venezuelan equine encephalitis virus, NHP, USAMRIID, Use, Injection, Unitary state, Infection, Vaccine

The Phase 1 study, sponsored by PharmaJet, aims to identify the optimal dose, vaccination schedule and delivery system most suitable for use in subsequent broader clinical evaluations of the VEE DNA vaccine candidate.

Key Points: 
  • The Phase 1 study, sponsored by PharmaJet, aims to identify the optimal dose, vaccination schedule and delivery system most suitable for use in subsequent broader clinical evaluations of the VEE DNA vaccine candidate.
  • The VEE DNA vaccine candidate is being evaluated as part of a multi-year agreement between PharmaJet and the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency (DTRA) .
  • The study, in collaboration with USAMRIID, aims to further advance the clinical assessment of the vaccine with the PharmaJet Precision Delivery Systems: Tropis Intradermal (ID) and Stratis Intramuscular (IM).
  • The PharmaJet Precision Delivery Systems are optimized for field use and have also shown immunogenicity levels higher than with needle-syringe.